Trial
NCT04944784
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Cytokinetics
Collaborators
—
Condition
Amyotrophic Lateral Sclerosis
Intervention
Reldesemtiv
Why stopped
The DMC recommended the trial be discontinued due to futility following a planned second interim analysis.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-05